Piper Sandler has revised its price target for Soleno Therapeutics (SLNO, Financial), elevating it from $93 to $145, while maintaining an Overweight rating on the stock. This adjustment follows the approval of VYKAT XR, which has spurred positive feedback from investors, particularly appreciating the clarity of its label and trust in the company’s leadership to successfully introduce the product to the market.
With an upcoming Q1 update, Soleno's management is expected to disclose preliminary data related to start forms, further influencing investor sentiment. Piper Sandler's analyst Yasmeen Rahimi emphasizes Soleno as one of the standout performers in what is currently a challenging market environment. The firm remains optimistic about Soleno's strategic position and potential growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Soleno Therapeutics Inc (SLNO, Financial) is $105.56 with a high estimate of $145.00 and a low estimate of $81.00. The average target implies an upside of 46.06% from the current price of $72.27. More detailed estimate data can be found on the Soleno Therapeutics Inc (SLNO) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Soleno Therapeutics Inc's (SLNO, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
